Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

July 31, 2023

Study Completion Date

February 28, 2027

Conditions
Myelofibrosis
Interventions
DRUG

Pacritinib

Patients receive up to 4 cycles of pacritinib before allo-SCT

Trial Locations (12)

Unknown

BE-Antwerpen-ZNASTUIVENBERG, Antwerp

BE-Gent-UZGENT, Ghent

BE-Leuven-UZLEUVEN, Leuven

BE-Roeselare-AZDELTA, Roeselare

NL-Amsterdam-AMC, Amsterdam

NL-Amsterdam-VUMC, Amsterdam

NL-Groningen-UMCG, Groningen

NL-Maastricht-MUMC, Maastricht

NL-Nijmegen-RADBOUDUMC, Nijmegen

NL-Rotterdam-EMCDANIEL, Rotterdam

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Utrecht-UMCUTRECHT, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

collaborator

CTI BioPharma

INDUSTRY

lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER